Southern California Compounding Pharmacy, LLC, San Diego, CA
Is Southern California Compounding Pharmacy, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Southern California Compounding Pharmacy, LLC hold a California pharmacy license?
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.
Has Southern California Compounding Pharmacy, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (May 14, 2020) and 1 FMD-145 letter (May 14, 2020) for Southern California Compounding Pharmacy, LLC. State board actions: record found. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses lists 2 actions: “Through a disciplinary action of the board, the license is revoked, the revocation is stayed, and the license placed on probation for four years, and is subject to the terms and conditions in the decision” dated Dec 15, 2014 on license PHY 49147 and “Through a disciplinary action of the board, the license is revoked, the revocation is stayed, and the license placed on probation for four years, and is subject to the terms and conditions in the decision” dated Dec 15, 2014 on license LSC 99510. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Southern California Compounding Pharmacy, LLC
- Location
- San Diego, CA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- May 14, 2020
- FDA Data Dashboard inspections
- 1 inspection: 1 VAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 5 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Southern California Compounding Pharmacy, LLC, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| May 14, 2020 | State referral letter | State Referral Letter Issued 05/14/2020 | Not linked by FDA |
| May 14, 2020 | FMD-145 letter | FMD-145 Letter Issued 05/14/2020 | FDA copy (archived) |
| Aug 1, 2019 | Form 483 | 483 Issued 08/01/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Southern California Compounding Pharmacy, LLC, San Diego, CA (FEI number 3010006900), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 1, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010006900 | 1099870 |
Form 483s FDA has published for this site
- Aug 1, 2019: Form 483 to Southern California Compounding Pharmacy, LLC, published Oct 21, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 8, 2019 to Aug 1, 2019: 5 observations
- Firm on the cover
- Southern California Compounding Pharmacy, LLC, 11125 Flintkote Avenue Suite F, San Diego, CA 92121
- FEI number
- 3010006900
- Establishment type on the cover
- Producer of Sterile and Non-Sterile Drug Products THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Personnel and environmental monitoring conducted within the ISO 5 Environments on a <Redacted B4> frequency are deficient.
Specifically, your firm does not perform growth promotion for each batch of media purchased or use a positive control when conducting <Redacted B4> gloved finger assessment and surface sampling. Your firm conducts gloved fingertip test and surface sampling as part of the compounding personnel qualification.
Observation 2
Gowning and aseptic practices are deficient.
Specifically, during the aseptic operation for Rx # <Redacted B4> on 7/10/19, we observed operator's head enter the ISO 5 Laminar Airflow Workstation (LAFW) during aseptic operations with exposed skin on forehead and cheeks. In addition, operator's skin was exposed at the ankle during aseptic operations and lower back skin was exposed during <Redacted B4> cleaning of the ISO 7 Buffer room.
Observation 3
The firm's cleaning and disinfecting procedure in the aseptic processing area are deficient.
Add Contlnuation Page
In addition. your firm utilizes the following non-sterile products to clean the ISO 5 LAFW:
(b) (4)
Observation 4
Smoke study conducted on 6/21/2019 to determine unidirectional airflows in ISO 5 LAFW was inadequate.
Specifically, the smoke study failed to adequately simulate dynamic conditions and did not provide adequate coverage to demonstrate unidirectional air flow during routine operations. ISO 5 LAFW is where the finn produces all its sterile drug products.
Observation 5
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, sampling plans, and test procedures designed to assure drug products confonn to appropriate standards of identity, strength, quality and purity.
Specifically, finished non-sterile drug products are not tested for the presence of microorganisms, for example: Ketoprofen 20%/Lidocaine 10%, lot no. 07419K20L10A, submitted fo <Redacted B4> process validation sample did not include a test for the presence of microorganisms.
Linked 483s whose text is not shown
- Aug 1, 2019: FDA document 164725: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Dec 15, 2014: “Through a disciplinary action of the board, the license is revoked, the revocation is stayed, and the license placed on probation for four years, and is subject to the terms and conditions in the decision.”, license PHY 49147, Southern California Compounding Pharmacy LLC, San Diego, CA. Board list
- Dec 15, 2014: “Through a disciplinary action of the board, the license is revoked, the revocation is stayed, and the license placed on probation for four years, and is subject to the terms and conditions in the decision.”, license LSC 99510, Southern California Compounding Pharmacy LLC, San Diego, CA. Board list
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- California State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.